CM Life Sciences's long-term debt is $65M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest long-term debt for CMLF is $65M as of June 2026. That compares with $60M in the prior-year period — up 8.8% year over year. Investors often review this figure alongside CM Life Sciences's historical trend and sector peers before judging valuation or financial health.
Over the past year, CMLF's long-term debt moved from $60M to $65M — a 8.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CM Life Sciences's operating scale or balance-sheet position.
A long-term debt figure of $65M for CMLF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting CMLF's long-term debt ($65M), review year-over-year change from $60M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.